Breaking News

OraSure Gets Govt. Support to Develop In-home Coronavirus Test

Receives BARDA contract for rapid oral fluid pan-SARS-coronavirus in-home self-test

By: Contract Pharma

Contract Pharma Staff

OraSure Technologies has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples. This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.   Built on OraSure’s OraQuick platform, the rapid test ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters